Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK),
 and pharmacodynamics (PD) of SBI-087 in subjects with Systemic Lupus Erythematosus (SLE).
Inclusion Criteria:

 -  Diagnosis of SLE (by greater than or equal to 4 American College of Rheumatology [ACR]
 Revised Criteria) greater than 6 months before study day 1.

 -  History of a positive antinuclear antibody (ANA) titer greater than or equal to 1:160
 or equivalent.

 Exclusion Criteria:

 -  Treatment with more than 20 mg of prednisone per day.

 -  Evidence of unstable clinically significant disease (e.g., cardiovascular,
 cerebrovascular, respiratory, or renal disease, or any other unstable serious
 disorder) other than SLE.

 -  History of cancer (other than resected cutaneous basal and squamous cell carcinoma or
 in situ cervical cancer) with less than 5 years' documentation of a disease-free
 state.